Peritoneal carcinomatosis of colorectal origin: Incidence and current treatment strategies

Annals of Surgery

Volumn 243, Issue 2, 2006, Pages 212-222

  Koppe, Manuel J ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a   Bleichrodt, Robert P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID;

CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; CYTOREDUCTIVE SURGERY; FOLLOW UP; HUMAN; LAPAROTOMY; MORBIDITY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REOPERATION; REVIEW; SYSTEMIC THERAPY; TREATMENT INDICATION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CARCINOMA; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; INCIDENCE; LEUCOVORIN; NEOPLASM SEEDING; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 31844444755     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000197702.46394.16     Document Type: Review

References (88)

1. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. 1996;82:79-100.
2. Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin North Am. 2003;12:585-603.
3. Mukherjee A, Parvaiz A, Cecil TD, et al. Pseudomyxoma peritonei usually originates from the appendix: a review of the evidence. Eur J Gynaecol Oncol. 2004;25:411-414.
4. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364-367.
5. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16:83-97.
6. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254-261.
7. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg. 1999;384:576-587.
8. Ceelen WP, Hesse U, De Hemptinne B, et al. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. Br J Surg. 2000;87:1006-1015.
9. Bosch B, Guller U, Schnider A, et al. Perioperative detection of disseminated tumour cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg. 2003;90:882-888.
10. Culler U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg. 2002;236:768-775.
11. Horattas MC, Evasovich MR, Topham N. Colorectal carcinoma and the relationship of peritoneal cytology. Am J Surg. 1997;174:334-337.
12. Kanellos I, Demetriades H, Zintzaras E, et al. Incidence and prognostic value of positive peritoneal cytology in colorectal cancer. Dis Colon Rectum. 2003;46:535-539.
13. Kim SH, Milsom JW, Gramlich TL, et al. Does laparoscopic versus conventional surgery increase exfoliated cancer cells in the peritoneal cavity during resection of colorectal cancer? Dis Colon Rectum. 1998; 41:971-978.
14. Ojima H, Sasaki S, Fujisawa T, et al. Utility of serosal stamp cytology as an indicator for high-risk peritoneal metastasis in colorectal cancer surgery. Hepatogastroenterology. 2003;50:87-90.
15. Solomon MJ, Egan M, Roberts RA, et al. Incidence of free colorectal cancer cells on the peritoneal surface. Dis Colon Rectum. 1997;40: 1294-1298.
16. Uras C, Altinkaya E, Yardimci H, et al. Peritoneal cytology in the determination of free tumour cells within the abdomen in colon cancer. Surg Oncol. 1996;5:259-263.
17. Wind P, Norklinger B, Roger V, et al. Long-term prognostic value of positive peritoneal washing in colon cancer. Scand J Gastroenterol. 1999;34:606-610.
18. Yamamoto S, Akasu T, Fujita S, et al. Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. Jpn J Clin Oncol. 2003;33:33-37.
19. Yang SH, Lin JK, Lai CR, et al. Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol. 2004;87:167-173.
20. Zeng Z, Cohen AM, Hajdu S, et al. Serosal cytologie study to determine free mesothelial penetration of intraperitoneal colon cancer. Cancer. 1992;70:737-740.
21. Cass AW, Million RR, Pfaff WW. Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum. Cancer. 1976;37:2861-2865.
22. Eisenberg B, Decosse JJ, Harford F, et al. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer. 1982;49: 1131-1134.
23. Gilbert JM, Jeffrey I, Evans M, et al. Sites of recurrent tumour after 'curative' colorectal surgery: implications for adjuvant therapy. Br J Surg. 1984;71:203-205.
24. Malcolm AW, Perencevich NP, Olson RM, et al. Analysis of recurrence patterns following curative resection for carcinoma of the colon and rectum. Surg Gynecol Obstet. 1981;152:131-136.
25. Mendenhall WM, Million RR, Pfaff WW. Patterns of recurrence in adenocarcinoma of the rectum and rectosigmoid treated with surgery alone: implications in treatment planning with adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9:977-985.
26. Minsky BD, Mies C, Recht A, et al. Resectable adenocarcinoma of the rectosigmoid and rectum: I. Patterns of failure and survival. Cancer. 1988;61:1408-1416.
27. Olson RM, Perencevich NP, Malcolm AW, et al. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer. 1980;45:2969-2974.
28. Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the proximal colon: sites of initial dissemination and patterns of recurrence following surgery alone. Cancer. 1984;53:360-367.
29. Gunderson LL, Sosin H, Levitt S. Extrapelvic colonareas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1985;11:731-741.
30. Tong D, Russell AH, Dawson LE, et al. Second laparotomy for proximal colon cancer: sites of recurrence and implications for adjuvant therapy. Am J Surg. 1983;145:382-386.
31. Russell AH, Pelton J, Reheis CE, et al. Adenocarcinoma of the colon: an autopsy study with implications for new therapeutic strategies. Cancer. 1985;56:1446-1451.
32. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638-646.
33. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-1550.
34. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989;63:364-367.
35. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-363.
36. Verwaal VJ, Van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-3743.
37. Meigs JV. Tumors of the Female Pelvic Organs. New York: McMillan, 1934.
38. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-104.
39. Griffiths CT, Parker LM, Fuller AF Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep. 1979;63:235-240.
40. Munnell EW. The changing prognosis and treatment in cancer of the ovary: a report of 235 patients with primary ovarian carcinoma 1952-1961. Am J Obstet Gynecol. 1968;100:790-805.
41. Spratt JS, Adcock RA, Sherrill W, et al. Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980;40:253-255.
42. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-260.
43. Sugarbaker PH, Kern K, Lack E. Malignant pseudomyxoma peritonei of colonie origin: natural history and presentation of a curative approach to treatment. Dis Colon Rectum. 1987;30:772-779.
44. Sugarbaker PH. Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment. Langenbecks Arch Chir. 1988;373:189-196.
45. Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin North Am. 2003;12:703-727.
46. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin North Am. 2003; 12:689-701.
47. Sarnaik AA, Sussman JJ, Ahmad SA, et al. Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. Surg Oncol Clin North Am. 2003;12:849-863.
48. Carmignani CP, Ortega-Perez G, Sugarbaker PH. The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol. 2004;30:391-398.
49. Culliford AT, Brooks AD, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol. 2001;8:787-795.
50. Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518-521.
51. Elias D, Pocard M, Sideris L, et al. Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004;91:455-456.
52. Glehen O, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004;91:747-754.
53. Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer. 1996;77:2622-2629.
54. Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004;90:403-407.
55. Pilati P, Mocellin S, Rossi CR, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol. 2003;10:508-513.
56. Schneebaum S, Arnold MW, Staubus A, et al. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol. 1996;3:44-50.
57. Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11:178-186.
58. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221:124-132.
59. Sugarbaker PH, Schellinx ME, Chang D, et al. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg. 1996;20:585-591.
60. Verwaal VJ, van Tinteren H, Van Ruth S, et al. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739-746.
61. Verwaal VJ, Boot H, Aleman BM, et al. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11:375-379.
62. Verwaal VJ, Zoetmulder FA. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2004;30:280-285.
63. Verwaal VJ, van Tinteren H, Ruth SV, et al. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004;85:61-67.
64. Witkamp AJ, de Bree E, Kaag MM, Boot H, et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2001;37:979-984.
65. Kecmanovic DM, Pavlov MJ, Ceranic MS, et al. Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31:147-152.
66. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284-3292.
67. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71-76.
68. Verwaal VJ, Van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21: 3737-3743.
69. Esquivel J, Vidal-Jove J, Steves MA, et al. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery. 1993; 113:631-636.
70. Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863-869.
71. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790-796.
72. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with carcinomatosis. In: Sugarbaker PH, ed. Peritoneal Carcinomatosis: Principles of Management. Boston: Kluwer Academic, 1996:359-374.
73. Langenhoff BS, Krabbe PF, Wobbes T, et al. Quality of life as an outcome measure in surgical oncology. Br J Surg. 2001;88:643-652.
74. Eisenkop SM, Friedman RL, Wang HJ. Secondary cytoreductive surgery for recurrent ovarian cancer: a prospective study. Cancer. 1995;76: 1606-1614.
75. Le T, Leis A, Pahwa P, et al. Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstet Gynecol Surv. 2003;58:749-758.
76. McQuellon RP, Loggie BW, Fleming RA, et al. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65-73.
77. McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155-162.
78. Chau I, Cunningham D. Adjuvant therapy in colon cancer: current status and future directions. Cancer Treat Rev. 2002;28:223-236.
79. Comella P, Casaretti R, Crucitta E, et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer. 2002;86:1871-1875.
80. Comella P, Crucitta E, De Vita F, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol. 2002;13:866-873.
81. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol. 2003; 21:2059-2069.
82. Vlems FA, Ruers TJ, Punt CJ, et al. Relevance of disseminated tumour cells in blood and bone marrow of patients with solid epithelial tumours in perspective. Eur J Surg Oncol. 2003;29:289-302.
83. Vlems FA, Wobbes T, Punt CJ, et al. Detection and clinical relevance of tumor cells in blood and bone marrow of patients with colorectal cancer. Anticancer Res. 2003;23:523-530.
84. Vlems FA, Diepstra JH, Punt CJ, et al. Detection of disseminated tumour cells in blood and bone marrow samples of patients undergoing hepatic resection for metastasis of colorectal cancer. Br J Surg. 2003;90:989-995.
85. Gertsch P. A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments. Surg Oncol Clin North Am. 2003;12:531-541.
86. Sugarbaker PH. Clinical research to standard of care: when does the transition occur? Ann Surg Oncol. 2003;10:825-826.
87. Verwaal VJ. Cytoreduction and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis of colorectal origin [Thesis/Dissertation]. Amsterdam, University of Amsterdam, 2004.
88. Mansfield PF. Management of peritoneal carcinomatosis: is an answer at hand? Ann Surg Oncol. 2003;10:827-828.